Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
LeukemiaLeukemiaLeukemia
Lung Cancer
LymphomaLymphomaLymphomaLymphoma
Rare CancersRare Cancers
Sarcoma
Skin Cancer/Melanoma
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
LeukemiaLeukemiaLeukemia
Lung Cancer
LymphomaLymphomaLymphomaLymphoma
Rare CancersRare Cancers
Sarcoma
Skin Cancer/Melanoma
Thyroid Cancer
    • Subscribe
Advertisement

Article

September 22, 2015

Shaji Kumar on Treatment-Related Adverse Events From Monoclonal Antibodies

Author(s):

Shaji Kumar

Shaji Kumar, professor of medicine, Division of Hematology, Mayo Clinic, discusses common treatment-related adverse events from monoclonal antibodies in patients with multiple myeloma.

Shaji Kumar, professor of medicine, Division of Hematology, Mayo Clinic, discusses common treatment-related adverse events from monoclonal antibodies in patients with multiple myeloma.

The main adverse event that is seen is infusion reactions, Kumar says. These reactions are easily managed and, even so, usually go away on their own.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Photo of Dr. Rosario Ligresti
Image of women with text.
CAR-T cell therapies are now being explored for the treatment of solid tumors like gliomas, Dr. Tanja A. Gruber explained in an interview with CURE.
Related Content
Advertisement
Multiple myeloma is a chronic blood cancer affecting plasma cells, but with today’s treatments many patients can manage symptoms and live fulfilling lives.
August 23rd 2025

What Does Multiple Myeloma Mean?

Gina Mauro
Top Headlines on CAR-T Cell Therapy
August 23rd 2025

Top Headlines on CAR-T Cell Therapy

Alex Biese Brielle Benyon
The FDA declined approval of Darzalex Faspro for newly diagnosed, transplant-ineligible multiple myeloma in its current form: © stock.adobe.com.
August 23rd 2025

FDA Gives Complete Response Letter for Darzalex Faspro Quadruplet Regimen

Spencer Feldman
Health Care Worker Discusses Cancer Diagnosis and Vaccine Experience While on the Frontlines of the COVID-19 Pandemic
August 23rd 2025

Health Care Worker Discusses Cancer Diagnosis and Vaccine Experience While on the Frontlines of the COVID-19 Pandemic

Jamie Cesanek
SAR446523, an investigational antibody targeting GPRC5D, received FDA orphan drug status: © stock.adobe.com.
August 23rd 2025

FDA Grants Orphan Drug Status to SAR446523 for Relapsed Myeloma

Spencer Feldman
Image of FDA sign.
August 23rd 2025

FDA Votes Against Proposed Blenrep Treatment Combo’s for Multiple Myeloma

Ryan Scott
Related Content
Advertisement
Multiple myeloma is a chronic blood cancer affecting plasma cells, but with today’s treatments many patients can manage symptoms and live fulfilling lives.
August 23rd 2025

What Does Multiple Myeloma Mean?

Gina Mauro
Top Headlines on CAR-T Cell Therapy
August 23rd 2025

Top Headlines on CAR-T Cell Therapy

Alex Biese Brielle Benyon
The FDA declined approval of Darzalex Faspro for newly diagnosed, transplant-ineligible multiple myeloma in its current form: © stock.adobe.com.
August 23rd 2025

FDA Gives Complete Response Letter for Darzalex Faspro Quadruplet Regimen

Spencer Feldman
Health Care Worker Discusses Cancer Diagnosis and Vaccine Experience While on the Frontlines of the COVID-19 Pandemic
August 23rd 2025

Health Care Worker Discusses Cancer Diagnosis and Vaccine Experience While on the Frontlines of the COVID-19 Pandemic

Jamie Cesanek
SAR446523, an investigational antibody targeting GPRC5D, received FDA orphan drug status: © stock.adobe.com.
August 23rd 2025

FDA Grants Orphan Drug Status to SAR446523 for Relapsed Myeloma

Spencer Feldman
Image of FDA sign.
August 23rd 2025

FDA Votes Against Proposed Blenrep Treatment Combo’s for Multiple Myeloma

Ryan Scott
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.